Podcasts about hpv

Hi and welcome to How Humans Heal. In this episode, I want to talk about something that affects so many of us — testing positive for high-risk HPV — and more importantly, what you can actually do about it. I'll be walking you through the five most common underlying susceptibilities that prevent your immune system from clearing the virus, because understanding this is the key to finally getting rid of HPV for good. I'm here to help you! LINKS FROM THE EPISODE:   Sign up for Dr. Doni's 5-Day HPV Workshop: https://doctordoni.com/HPV-workshop/   Schedule A Chat With Dr. Doni: https://intakeq.com/new/hhsnib/vuaovx    Read the full episode notes and find more information: https://doctordoni.com/blog/podcasts/ MORE RESOURCES FROM DR. DONI:   Quick links to social media, free guides and programs, and more: https://doctordoni.com/links     Disclosure: Some of the links in this post are product links and affiliate links and if you go through them to make a purchase I will earn a commission at no cost to you. Keep in mind that I link these companies and their products because of their quality and not because of the commission I receive from your purchases. The decision is yours, and whether or not you decide to buy something is completely up to you.

First, we talk to The Indian Express' Anonna Dutt about the central government's plan to start a HPV vaccine drive. The Human papillomavirus or HPV is an extremely common virus, and is the main cause of cervical cancer. The goal of the campaign is to prevent cervical cancer, which remains one of the most common cancers among Indian women.Next, we talk to The Indian Express' Alok Singh about a new type of extortion rackets emerging in Delhi. These rackets involve threats delivered via internet calls and voice notes and gang members being selected through Instagram and Facebook pages Alok talks about these gangs, how they operate and their new targets. (12:30)Lastly, we talk about a resolution that has been approved by the Union Cabinet to change Kerala's name to Keralam. (21:30)Hosted by Niharika NandaProduced by Shashank Bhargava, Niharika Nanda, and Ichha Sharma Edited and mixed by Suresh Pawar

मोदी सरकार पर बरसे राहुल गांधी. लखनऊ में नमाज बनाम हनुमान चालीसा. यूथ कांग्रेस के अध्यक्ष गिरफ्तार. संसद की स्थायी समिति ने क्या प्रस्ताव पास किया. अविमुक्तेश्वरानंद पहुंचे इलाहाबाद हाईकोर्ट. केरल का नाम अब केरलम होगा. देशभर में HPV वैक्सीनेशन होगा शुरू. एमनेस्टी इंटरनेशनल ने पाकिस्तान पर उठाया सवाल. अमेरिका-चीन में बढ़ी टेंशन और टी-20 वर्ल्ड कप में पाकिस्तान का मुकाबला इंग्लैड से. सिर्फ 5 मिनट में सुनिए शाम 4 बजे तक की बड़ी ख़बरें.

India is set to roll out a nationwide HPV vaccination programme for 14-year-old girls later this month. The vaccine will be provided free of cost through government health centres. Each year, nearly 1.15 crore girls will become eligible for the shot. The government says this is a major step in preventing cervical cancer in India. But what exactly is HPV, and why is the vaccine important?See omnystudio.com/listener for privacy information.

Danfoss Case Controllers Enables and Control, Does GoogleTranslate Do Scottish?? Episode-508Brett Wetzel and first-time guest Kevin Compass kick off the Advanced Refrigeration Podcast in a chaotic mood after tech failures, traffic, and a rough week on a large grocery-store refrigeration job where electricians are slowing progress, skipping work on energized circuits, and delaying rack startup. They talk about traveling, hotel safety concerns, sleep deprivation, and returning the following week because verification is only partially complete and the rack couldn't be started. The conversation shifts into Danfoss case control and pack controller details, including correcting earlier misunderstandings about fan shutdown logic being handled automatically by the pack controller if programmed correctly. Brett walks through Danfoss thermostat control settings (on/off vs modulating), notes recommended minimum modulation percentages (around 3.6–4), and discusses guidance from Brian Rogers about avoiding modulating on dual-temp islands unless using an EPR, especially on CO2 systems due to potential icing issues. They explain S3/S4 sensor weighting (inlet vs discharge air), caution against using weighted control where return air can be blocked (turkey, produce, beer cases), and discuss how modulating control can reduce cycling and improve rack stability—especially on low-temp circuits that affect medium-temp load and BGV stability. They debate CO2 ejector versus high-pressure valve operation, with Brett noting updated information that ejectors run as primary until high utilization before the HPV opens. The episode also covers Danfoss network scheduling for case enable/shutdown staging, group-based defrost schedules, why long stage delays can cause short cycling after power blips, the value of adding minimum loop protections, and the confusion of chained controller calculations. They end by noting a potential wiring/relay issue on ejector solenoids (not all on solid-state relays), joking about communication challenges with a Scottish colleague, and signing off as Brett heads to sleep before an early flight.

Brett Wetzel and first-time guest Kevin Compass kick off the Advanced Refrigeration Podcast in a chaotic mood after tech failures, traffic, and a rough week on a large grocery-store refrigeration job where electricians are slowing progress, skipping work on energized circuits, and delaying rack startup. They talk about traveling, hotel safety concerns, sleep deprivation, and returning the following week because verification is only partially complete and the rack couldn't be started. The conversation shifts into Danfoss case control and pack controller details, including correcting earlier misunderstandings about fan shutdown logic being handled automatically by the pack controller if programmed correctly. Brett walks through Danfoss thermostat control settings (on/off vs modulating), notes recommended minimum modulation percentages (around 3.6–4), and discusses guidance from Brian Rogers about avoiding modulating on dual-temp islands unless using an EPR, especially on CO2 systems due to potential icing issues. They explain S3/S4 sensor weighting (inlet vs discharge air), caution against using weighted control where return air can be blocked (turkey, produce, beer cases), and discuss how modulating control can reduce cycling and improve rack stability—especially on low-temp circuits that affect medium-temp load and BGV stability. They debate CO2 ejector versus high-pressure valve operation, with Brett noting updated information that ejectors run as primary until high utilization before the HPV opens. The episode also covers Danfoss network scheduling for case enable/shutdown staging, group-based defrost schedules, why long stage delays can cause short cycling after power blips, the value of adding minimum loop protections, and the confusion of chained controller calculations. They end by noting a potential wiring/relay issue on ejector solenoids (not all on solid-state relays), joking about communication challenges with a Scottish colleague, and signing off as Brett heads to sleep before an early flight.

Jolanta Sobierańska-Grenda o zamykanych porodówkach, o przeglądzie grup zwolnionych z płacenia składki zdrowotnej, o szczepieniu przeciwko HPV, sytuacji szpitali, planie rządu i proteście medyków

It is well-established that health issues that appear on a physical level are often related to or even caused by unaddressed emotions and/or energetic imbalances. This is also true for high-risk HPV, abnormal Pap smears, and cervical and vaginal cancer risk. As humans, when we experience symptoms — a headache, a skin rash, pain, or HPV and an abnormal Pap result — we tend to think of them as occurring only on a physical level. But research has demonstrated that these health issues are related to emotional and spiritual, or energetic, levels as well. When there is an imbalance, trauma, or unaddressed emotional or energetic issue, it can absolutely influence us physically. So, when something shows up as a symptom or diagnosis, it may be related to something happening emotionally or spiritually. I've been working with thousands of cases for over 25 years, so I've had a great deal of opportunity to observe these connections. When a patient comes to me with an abnormal Pap smear, autoimmunity, migraines, or a skin rash, I begin by looking at physical imbalances — hormones, nutrient deficiencies, microbiome issues for example. But I've learned that it doesn't stop there. We also need to consider what's happening emotionally and spiritually, which brings us to the influence of stress and trauma on the human experience. In this episode I'm going to discuss the mind, body, spirit connection to health, and how recovery from stress and trauma can help eliminate or reverse health issues on a physical, as well as emotional, and spiritual level. I'm here to help you! LINKS FROM THE EPISODE:   Sign up for Dr. Doni's 5-Day HPV Workshop: https://doctordoni.com/HPV-workshop/   Schedule A Chat With Dr. Doni: https://intakeq.com/new/hhsnib/vuaovx    Read the full episode notes and find more information: https://doctordoni.com/blog/podcasts/ MORE RESOURCES FROM DR. DONI:   Quick links to social media, free guides and programs, and more: https://doctordoni.com/links     Disclosure: Some of the links in this post are product links and affiliate links and if you go through them to make a purchase I will earn a commission at no cost to you. Keep in mind that I link these companies and their products because of their quality and not because of the commission I receive from your purchases. The decision is yours, and whether or not you decide to buy something is completely up to you.

Dr. Monty Pal and Dr. Ari Rosenberg discuss the evolution of treatment strategies in head and neck cancers, including the challenges of treating both HPV-positive and HPV-negative disease and the emergence of blood-based biomarkers to advance personalized therapy across different subtypes. TRANSCRIPT Dr. Monty Pal: Hello and welcome to the ASCO Daily News Podcast. I'm your host, Dr. Monty Pal. I'm a medical oncologist, professor, and vice chair of academic affairs at the City of Hope Comprehensive Cancer Center in Los Angeles. Today, we're going to explore the evolving landscape of treatment strategies in head and neck cancer management, including locoregionally advanced head and neck squamous cell carcinoma, which happens to be on the rise in United States, in part due to spike in HPV-mediated oropharyngeal cancers. We're also going to discuss the emerging strategies of using blood-based biomarkers to really advance personalized therapy. Joining me for this discussion is Dr. Ari Rosenberg. He's a medical oncologist focused on head and neck cancer, and he's an associate professor – congratulations on the recent promotion – at the University of Chicago. The University of Chicago has really produced luminaries in this field, Dr. Rosenberg included. I've had the pleasure of getting to know Dr. Ezra Cohen over the years, who really had his grounding there, and of course Everett Vokes, former ASCO President. I'm really looking forward to this conversation, Ari. Thanks so much for joining us. Dr. Ari Rosenberg: Thanks, Monty. Thanks for the invitation. Dr. Monty Pal: You got it. And just a quick note for our listeners, our full disclosures are going to be in the transcript at the end of this episode. So let's start with the basics, if you don't mind. So, head and neck cancers are very diverse and they're challenging, right? In the sense that they're near vital organs, the treatments, you know, as we all saw during fellowship, if not now in clinical practice. They can really have such a major impact on vital organ function, speech, swallowing, et cetera. Can you just comment on head and neck cancers that are on the rise in the U.S.? I alluded to this briefly. Particularly, we've heard this in the context of colorectal cancer and so forth. Are you actually seeing younger adults being affected by this? Dr. Ari Rosenberg: Yeah, thanks for that. The vast majority of head and neck cancers are head and neck squamous cell carcinomas, as I'm sure many of the listeners recall as well from fellowship or their current training. And as you alluded to, the organ function, long-term and functional quality of life outcomes are quite important, particularly in the context that these develop in high value real estate, parts of our head and neck area that we use for speaking, swallowing, all sorts of other essential functions as well. As you also alluded to, we think of this in two different particular subtypes of head and neck cancer. The historical head and neck cancer from 50, 60 years ago was almost exclusively related to carcinogen exposure, tobacco, alcohol use, and that subtype of carcinogen-induced head and neck cancer has been slowly declining. However, over the last now several decades, we've been seeing an increase in primary oropharyngeal squamous cell carcinoma, mostly tonsil, base of tongue. These are attributable to HPV, human papillomavirus exposure. And that's now the majority of the head and neck cancers that we tend to see in our clinic. As you also alluded to, these have very different prognoses as well. HPV-related head and neck cancer has a much more favorable prognosis where much of the interest has been in can we de-intensify to optimize long-term function? But then the non-HPV-related head and neck cancer, or what we call HPV-negative head and neck cancer, continue to be very, very challenging. We only managed to cure about half of these folks, with many of these patients developing the current disease. These patients, in addition to being difficult to treat, also have major impacts both in terms of the treatments they undergo as well as their disease that can impact their function and quality of life. And you hinted at this a little bit, but we have been seeing an increase in younger patients with HPV-negative head and neck cancer as well, which is quite concerning. Younger patients, oftentimes never smokers, never drinkers, who are developing non-HPV-negative head and neck cancer. And that's been a little bit of a more recent trend that we've been seeing as well. So, definitely a lot of work to be done to optimize and improve outcomes across all of these different head and neck cancer subtypes. Dr. Monty Pal: I mean, I'm just curious, you know, in the context of colorectal cancer, one of the things that we talk about is the potential role of the microbiome driving some of these young-onset cancers with, you know, perhaps there being an impact on, for instance, inflammation and the gut and what have you. Tell me about head and neck cancer. Is this anything known as to why younger patients might be getting diagnosed with non-HPV type cancers? It's odd to me. Dr. Ari Rosenberg: Yeah, it's a great question. A lot of people are working on it. I think we folks have hypotheses, but it hasn't totally panned out exactly what's going on there. It does have a little bit more of a tendency towards women, whereas historically head and neck cancer is much more common in men than it is in women. But lots of people working on that, whether it's related to chronic inflammation, whether it's related to the microbiome. Whether it's related to dental exposure, dental work. So, a lot of folks trying to parse that out because I agree with you, it needs to be identified alongside improving treatment paradigms for these patients, the young ones and the older patients as well. Dr. Monty Pal: Interesting, interesting. You know, one of the phenomena that was sort of coming around when I was in training 25 years ago was this role of sort of induction therapy for head and neck cancers. And of course, it's really come full circle now to include checkpoint inhibitors and so forth. Tell me a little bit about this and how you apply it, maybe in an HPV-mediated context, maybe in a non-HPV context. Dr. Ari Rosenberg: Yeah, absolutely. Induction chemotherapy, as you alluded to, or neoadjuvant chemotherapy, depending on what the locoregional treatment approach is. Similar to other cancer types where systemic control early on has many potential advantages in this setting. Now, in head and neck cancer, even though induction chemotherapy is quite active in head and neck cancer, both HPV-positive and HPV-negative with pretty good response rates. A survival advantage for all comers with local regionally advanced disease remains unproven. There's been two randomized trials, both underpowered, but essentially did not show a survival advantage, showing that induction chemotherapy for all patients with locoregionally advanced and neck cancer can't be justified for a survival advantage. That being said though, there remains a number of potential advantages of giving induction or neoadjuvant chemotherapy, of course, improving systemic control and debulking the disease early on has potential advantages, and predicting the responsiveness to subsequent radiation treatment. We know for some time in head and neck cancer that the percentage of shrinkage or the response to induction chemotherapy actually predicts outcome related to radiation as a dynamic biomarker where response can be used to select patients, for example, for de-escalated radiation has been an area of active investigation, active research. And it also remains a key opportunity to evaluate predictive biomarkers and understanding pre and post treatment to better understand the biology. I'll just add to your question that recently over this past year, we also saw phase 3 data for neoadjuvant immunotherapy for a subset of head and neck cancer that is surgically resectable. And so that's reintroducing the potential benefit in the immunotherapy era of incorporating immunotherapy in the neoadjuvant or the induction setting as part of the evolving treatment paradigm for these diseases. Dr. Monty Pal: That's really interesting. And you kind of alluded to already several topics that I plan to hit on, you know, for instance, the role of immune checkpoint inhibitors, induction, chemotherapy, and so forth. And you started to touch on biomarkers. And of course, I think that's something near and dear to many of us in academic oncology. One thing that we've started talking a lot about in the context of colorectal cancer is circulating tumor DNA. How do you think this might fit in the context of head and neck cancer? Can you give us a flavor for that? Dr. Ari Rosenberg: Yeah, absolutely. In head and neck cancer, the current landscape is most developed for circulating tumor DNA for HPV-related head and neck cancer. The advantage of HPV-related head neck cancer is that you have a distinctive HPV DNA that does tend to spill out into the peripheral blood and can be detected using various different blood-based assays. And because of that advantage as a tissue agnostic approach, it turns out that a number of HPV DNA plasma assays are actually quite sensitive and quite specific. And a number of them have indeed been commercialized. Of course, not only for detecting a baseline, but also grading responsiveness during treatment and probably most importantly in the post-treatment surveillance setting, the detection of HPV DNA in the plasma remains a very important and substantial predictor of developing recurrent disease. There's been a number of trials that have been emerging looking at ctDNA and HPV-related head and neck cancer, using it, for example, as a strategy to deescalate patients. That was something we saw this past ASCO from the Dana-Farber group, and also using it to early detect recurrence and potentially intervene earlier for patients with minimal residual disease positivity. So, that remains evolving and as many folks are, I think, already using it in the clinic. But ctDNA also has a lot of potential for HPV-negative head and neck cancer. This is actually a bit more challenging to develop because you don't have that HPV DNA that you can track predictably because the tumor is an HPV- negative disease are much more heterogeneous, but there are a number of data that are coming out both for personalized assays such as Signatera or some of the other assays that require tumor. Unlike colon cancer, which you referenced, where most patients get surgery upfront, in head and neck cancer, many of the patients receive non-surgical pre-chemoradiation. So sometimes the amount of tumor available to generate a personalized assay is more limited and can be one of the challenges that we see in head neck cancer. But certainly that also seems to be emerging. And there's also further assays that are being developed for HPV-negative head neck cancers, such as methylomic signatures and others that may be tissue informed or tissue agnostic. And these are also emerging, particularly in the post-treatment surveillance setting as strong predictors of recurrent disease. So while we're certainly behind some of these other more common tumor types, colon cancer, lung cancer, we're right there with them and more and more trials are going report out, including a number of trials in our upcoming [University of Chicago] Head and Neck Cancer Symposium where I'll be presenting some data and others in the field will be presenting some data looking at ctDNA both for HPV-positive and for HPV- negative to try to improve outcomes for these patients. Dr. Monty Pal: That's so interesting. I've got to tell you that in kidney cancer, what I deal with day to day is a very low shedding disease, right? So techniques as opposed to ctDNA looking for tumor-informed information, that might be less preferred to something like methylomics where you might not necessarily be so contingent on what's happening in the primary tumor. I'm really interested in you mentioning that. Just a point of clarification, this is something I'm trying to wrap my head around. You'd mentioned circulating tumor HPV DNA, right? I assume this is markedly different from just looking for HPV titers in the patient, right? So is this actually incorporated elements of HPV within, you know, essentially host genome, if you will? Dr. Ari Rosenberg: Yeah, correct. This is circulating tumor HPV DNA. And we think of it biologically as a plasma-based tumor DNA biomarker that's specific for HPV-related head and neck cancers. Dr. Monty Pal: Got it, got it. It makes me wonder whether or not this might be applicable to diseases like cervical cancer and so forth where there's also extensively, you know, biology driven by HPV. Is that fair? Dr. Ari Rosenberg: Yes, definitely. And in the head and neck cancer field, much of this ctDNA actually was derived from a different viral mediated head neck cancer, is less common in the U.S., but nasopharyngeal cancer, which is oftentimes associated with EBV. That has been a biomarker for quite some time in nasopharyngeal cancer. Of course, in places where EBV-associated nasopharyngeal cancer, is endemic, such as East Asia, this has been around for quite some time, but we've been using that in the U.S., and there's been trials that have used EBV DNA plasma to predict recurrence and stratify for adjuvant treatment, for example. And so now with HPV, it's much more applicable to our US population because the vast majority of our head and neck cancer patients that we see in the US that are viral mediated in the US tend to be HPV-related. So having assays that we can use to improve outcomes for that biological subset remains of particular interest for us. Dr. Monty Pal: Yeah, that's fascinating. By the way, for the fellows listening, there's tons of boards pearls here that Dr. Rosenberg shared, EBV-associated cancers, the role of HPV and treatment association. So if you're recertifying anytime soon, I definitely think there's notes to take from this conversation indeed. I wanted to shift gears a little bit. And obviously, you're a prolific researcher. I don't think anyone goes through their fellowship in medical oncology without recounting these experiences of our head and neck patients really suffering from treatment-related toxicities. It's a real challenge. And I'm just wondering, I know a big body of work that you're focused on is really using multimodality treatment paradigms to perhaps reduce the cumulative treatment burden of patients with head and neck cancers. Can you talk about that a little bit? Dr. Ari Rosenberg: Yeah, definitely. Thanks for the question. And before I start going into some of the strategies, I'll just say that head and neck cancer, this is particularly for the fellows that are listening as well, just in reference to your prior comment, that this is really a multidisciplinary disease. At our center, all head and neck cancer patients are seen upfront at that first visit by all three specialties, med onc, rad onc, and surgery, because the choice and sequencing of modalities to optimize not only survival, but also functional quality of life outcome is so critical. And I think that's probably the biggest takeaway for anyone who treats a lot of head and neck cancer or will be treating a lot of head and neck cancer in the clinic. But in terms of more specific attempts at trying to optimize some of those parameters that you described, we really think about these separately in terms of HPV-positive and HPV-negative head and neck cancer. For HPV-positive head and neck cancer, the cure rates are quite high with chemo radiation, although not for everyone. There's still about 15, 10 to 15 % of folks that will develop a recurrence. But for the vast majority of patients, standard chemoradiation is quite a cure to therapy, but the toxicity associated with that can be quite substantial. And so there's been a number of attempts to try to deescalate treatment. It turns out that deescalating everyone with locoregionally advanced HPV-positive head and neck cancer is not a good strategy because it's not able to select out the patients that really do need full dose treatment. And we have seen some negative trials that show inferior outcomes when everyone is deescalated. But what does remain promising is again, trying to select out who the best candidates are for deescalated treatment. The folks at MSK have hypoxia imaging that they're using in trials that looks quite promising to select for the more favorable deescalatable biology. At our center, we've been interested in using induction chemotherapy to stratify response and select patients for deescalated treatment with excellent survival outcomes and reduce toxicity with deescalated treatment. And more recently, ctDNA that us and other groups, such as the Dana-Farber group, is using. And that also looks quite promising. Again, how do you select the patient who will do well with less radiation versus the ones that really need the full doses and volumes of radiation? And then for HPV-negative head and neck cancer, this is a much trickier disease because already the survival outcomes are not like we want it to be. Trying to figure out how to improve survival outcomes remains an important thing. Using immunotherapy seems to be one of the key cornerstones to that. But these are patients that also suffer from a lot of toxicity related to their treatment. We completed a trial not too long ago that we published this past year where we, in HPV-negative head and neck cancer patients, de-intensified the radiation for responders to neoadjuvant chemoimmunotherapy. And those patients did similar, if not even a little bit better, than the non-responders who got full dose treatment. So something that does warrant further investigation as well. How do we not only improve survival for those patients, but also reduce some of the long-term toxicities? Dr. Monty Pal: This is brilliant. I'm taking so many notes as you were mentioning these items. There are so many areas where I think the research crosses over. I already mentioned, know, ctDNA, for instance, and metabolomics and the places where that might apply to kidney cancer. The hypoxia imaging really caught my ear too. Obviously, kidney cancer is disease highly predicated on hypoxia. So thank you for all of this. We've got about a minute or so. So, I'm going to ask you for a really tall task here. Can you tell us what you foresee being some of the biggest challenges that sort of lie ahead and head and neck cancer. You've already kind of alluded to it with ongoing research, but if you had to pick maybe 2, 3 problems, the very most that we really need to get to and head and neck cancer, what would that be? Dr. Ari Rosenberg: Yeah, that's a great question. Obviously, lots of things to be done, but if I'm going to limit it to just a couple, I would say number one is really trying to improve the survival for HPV negative local regionally advanced head and neck cancer. We talked early on about how we are seeing, you know, of course we see many of these people that were smokers and drinkers, but also seeing these in younger patients, in patients without a history of tobacco use. Some of these are very biologically aggressive and we need better treatments beyond surgery, beyond chemo radiation, beyond immunotherapy to improve outcomes for these patients and cure more of them. So, I would say that's one big area. And the other is, which we didn't speak about so much in this talk, but remains one of the biggest challenges that we see in the clinic is the recurrent metastatic head and neck cancer patients. This is an incredibly challenging disease to treat, not only with poor survival, but also with substantial impacts on quality of life and function. mean, these are bad recurrences that cause a lot of pain, functional deficits, really impacts quality of life as well. So developing novel therapies, many of which are currently in clinical trials and many of which are currently continuing to be developed, remains so critical. How do we develop better systemic therapies, better targeted therapies, better biomarkers for recurrent metastatic head neck cancer to improve their survival and quality of life and functional outcomes. Those are the two big areas that require the most work at this time within the head and neck cancer field. Dr. Monty Pal: That's brilliant. I mean, I have to tell you I could probably talk to you all day about this, such a fascinating topic. It's a very exciting time in the field. Thank you, Dr. Rosenberg, for all your incredible contributions and thanks for sharing with us your insights on the ASCO Daily News Podcast. Dr. Ari Rosenberg: Yeah, and thanks for the introduction. Hope to do it again soon. Dr. Monty Pal: And many thanks to our listeners for your time today. If you value the insights that you hear from the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. More on today's speakers:      Dr. Monty Pal   @montypal  Dr. Ari Rosenberg @AriRosenbergMD Follow ASCO on social media:           ASCO on X     ASCO on Bluesky          ASCO on Facebook           ASCO on LinkedIn           Disclosures:        Dr. Monty Pal:       Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview      Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical      Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis  Dr. Ari Rosenberg:     Stock and Other Ownership Interests: Privo Technologies Consulting or Advisory Role: Nanobiotix, EMD Serono, Vaccitech, Novartis, Eisai, Astellas Pharma, Regeneron, RAPT Therapeutics, Geovax Labs, Janssen, Summit Therapeutics Speakers' Bureau: Coherus Biosciences Research Funding (Inst.): Hookipa Biotech, EMD Serono, Purple Biotech, Bristol-Myers Squibb/Celgene, BeiGene, Abbvie, Astellas Pharma, Pfizer, Janux Therapeutics

In episode 68 of Going anti-Viral, Dr Ruanne Barnabas joins host Dr Michael Saag to discuss topic of a symposium session at the upcoming the Conference on Retroviruses and Opportunistic Infections (CROI) entitled Strategic and Resilient Responses to the Funding Crisis Across Africa. Dr Barnabas is the Chief of the Division of Infectious Diseases at Massachusetts General Hospital. Her work is focused on identifying effective and scalable HIV, HPV, and infectious diseases treatment and prevention strategies that increase access across diverse communities and promote equity in health. Dr Barnabas discusses the substantial progress made in global health, particularly in HIV treatment and prevention. She also discusses the impact of funding cuts from USAID on health systems and highlights with Dr Saag the importance of the US President's Emergency Plan for AIDS Relief (PEPFAR) in delivering effective care. Dr Barnabas outlines the presentations to be given at the upcoming symposium at CROI 2026 addressing the HIV funding crisis, emphasizing community resilience, and the future of health equity.0:00 – Introduction1:29 – Overview of global health funding at the end of 20244:03 – Success of PEPFAR and USAID10:25 – Funding cuts and their consequences12:48 – Overview of the CROI 2026 symposium on the HIV funding crisis in Africa16:28 – Community perspectives and impact of new technologies18:08 – Lessons learned from funding cuts21:13 – Looking ahead: future of HIV and global health programsResources:CROI 2026: https://www.croiconference.org/Going-anti-Viral: Episode 43 - Innovations in HIV Service Delivery: Building a Path Forward with Those Left Behind - Dr Izukanji Sikazwe__________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

O Juliano conheceu a Isabela, que foi o seu primeiro e único amor. Aos 20 anos eles se casaram, mas quando decidiram ter um filho, Isabela descobriu que tinha HPV e acusou o Juliano de traição. Só que, ele fez um teste escondido e deu negativo. Ao confrontar a esposa, ela confessou uma traição no começo do casamento. Hoje, ele ainda não sabe o que vai acontecer na relação deles, já que a única coisa em que ele acreditava era o amor.

Don't be surprised if you find yourself needing head and neck cancer surgery and your surgeon has an unexpected assistant: a robot. But it won't be R2D2 or C3P0 from Star Wars. Instead, the modern medical robot is a high-tech tool that surgeons use to perform sensitive tasks in hard-to-reach places. In this episode, Dr. Vivian Wu, a head and neck surgeon at Pacific Neuroscience Institute, takes us into the new world of robotic surgeries. Dr. Wu also tells us about some new tests that can show how successful someone's cancer treatment has been, without the need for invasive biopsies. She talks about how to prevent and treat Human Papillomavirus, or HPV, which has started showing up in people's mouths in greater numbers. Dr. Wu also emphasizes the important role a care “village” plays in a patient's treatment and recovery.

Last year the National Department of Health shared that Human Papillomavirus vaccinations will be conducted at public, special, private and independent schools by teams of healthcare workers. The Department has stressed that Cervical Cancer is highly preventable through the HPV vaccination. They further encouraged parents, caregivers and legal guardians to sign the consent form to ensure that their children do not miss out on life-saving vaccinations. But what IS HPV? Dr. Angelique Coetzee, South African general practitioner and former chair of the South African Medical Association, went into detail about this viral infection and why vaccination is important. Stacey also took a moment to share her own experience with HPV and cervical cancer. If you missed it live, listen in...

What does a pap smear test for, and what happens after an abnormal pap smear? In this episode of SHE MD, Mary Alice Haney interviews Dr. Thaïs Aliabadi to break down exactly what a pap smear is, how HPV affects cervical cancer risk, and what women need to know about abnormal results. A pap smear is a cervical cancer screening test that checks for precancerous and cancerous cells on the cervix. A pap smear does not test for ovarian cancer, uterine conditions, or all sexually transmitted infections. HPV testing is often performed at the same time because high risk HPV is the leading cause of cervical cancer.Can you have HPV with a normal Pap smear? What actually happens after an abnormal result? Dr. A answers these questions and more, explaining that while most HPV infections clear on their own within one to two years, monitoring and follow-up are key. The bottom line: cervical cancer is highly preventable with routine Pap and HPV screening—but annual well-woman visits are still essential for protecting your long-term health.Subscribe to SHE MD Podcast for expert tips on PCOS, Endometriosis, fertility, and hormonal balance. Share with friends and visit SHE MD website and Ovii for research-backed resources, holistic health strategies, and expert guidance on women's health and well-being.Sponsors:Premier Protein: Find your favorite flavor at PremierProtein.com or at Amazon, Walmart, and other major retailers.Midi Health - Ready to feel your best and write your second act script? Visit JoinMidi.com today to book your personalized, insurance-covered virtual visit. Bobbie: If you want to feed with confidence too, head to hibobbie.com — to the formula trusted by parents and loved by their babies — 700k and counting.Peloton - Let yourself run, lift, sculpt, push, and go. Explore the new Peloton Cross Training Tread+ at onepeloton.com What You'll Learn:What a pap smear actually tests for and what it does not screenHow HPV and pap smear testing work together to prevent cervical cancerWhat abnormal pap smear results like ASCUS, CIN1, CIN2, and CIN3 meanWhen a normal pap smear still requires follow up or colposcopyWhy regular pap smear screening makes cervical cancer almost entirely preventableKey Timestamps:00:00 Introduction02:00 What a pap smear tests for and what it does not check03:40 HPV explained: low risk vs high risk and why it's common05:15 Screening guidelines and why pap smear alone is not enough07:15 What types of results you can get back from a pap smear 17:20 When you need a colposcopy and what happens during the procedure22:15 Biopsy results and CIN staging explained34:00 Treatment options: cryotherapy, LEEP procedure, and cold knife cone35:40 Risks of aggressive LEEP and pregnancy considerations38:00 HPV dormancy and common misconceptions41:45 HPV vaccine recommendations and prevention43:00 Final takeaway: pap smear schedule vs well woman examKey Takeaways:A pap smear screens for cervical cancer and HPV, not STDs, ovarian cancer, or uterine conditionsHigh risk HPV, especially types 16 and 18, may require colposcopy even with a normal pap smearColposcopy and cervical biopsy confirm whether precancer cells are present and guide treatmentMost HPV infections clear naturally within one to two yearsCervical cancer is preventable with routine pap smear and HPV screening, but annual well woman exams remain essentialResources Mentioned in This Episode:

Top 5 Topics:- Why So Many People Can't Get Dental Care Right Now- The Shocking Truth About Sports Drinks, Sugar, and Your Teeth- Why Dentists Are Catching Diseases Doctors Miss- AI Is Taking Over Dentistry — Is That a Good Thing?- Corporate Dentistry vs. Patient Care: What Patients Should KnowQuotes & Wisdom:12:10 — “Gatorade will erode all your enamel off… I realized it in dental school.”14:28 — “I'm all about student athletes. I think it's a great way… it's great for school.”17:17 — “It was the best decision to go into dentistry… I didn't realize the art in it… and I was an artsy person.”21:33 — “I always felt supported… we would always help each other out.”25:38 — “It's gonna take a good 10, 20 years of research before we can actually put our foot down and say yes or no.”26:47 — “Quality of life… is much better when you're mobile.”33:08 — “We're losing power left and right.”40:33 — “As dentists… I absolutely see that patient more than their primary care doctor.”42:43 — “Preventative care is always the way.”48:27 — “If you just treat people right… the money comes.”1:05:08 — “A rising tide raises all ships.”Questions:10:06 — “How long were you upstate… and you got talked out of New Jersey—You never ended up working in New Jersey?”11:22 — “Where did you grow up on Long Island?”13:46 — “Did you play [goalie] all 4 years? …Do you keep up with it?”24:45 — “What do you think about the Japan growing teeth and stuff? How do you feel about that?”37:20 — “If all patients brushed/flossed every day… would fluoride in the water be necessary?”41:23 — “What do you feel about HPV testing of saliva?”Now available on:- Dr. Gallagher's Podcast & YouTube Channel- Long Island Dentists Podcast #7- Dose of Dental Podcast #206My watch in this episode = Tag Heuer Aquaracer Calibre 16 Chrono- 12.2025

本集節目由【夠酷就+1 防禦HPV 衛教宣導】合作播出男女1+1，一起防禦HPVHPV 是「人類乳突病毒」，是一種非常常見的病毒，多透過親密接觸傳染。每10人中有8個人就可能感染 HPV。一生單一伴侶感染機率60%，一生累積3~6位伴侶感染機率則高達90%。大部分HPV感染會自行清除，但90%男性感染HPV病毒無法自行產生抗體。男性每2位中，就有1位可能感染HPV。諮詢和施打HPV疫苗並不難，大多數全台灣家醫科、耳鼻喉科、婦產科、小兒科、泌尿科感染科，甚至醫美診所都可以隨到隨向醫師諮詢。更多衛教資訊歡迎上網搜尋『HPV』。

O balanço desta semana destaca o início da vacinação de 1,2 milhão de profissionais contra a dengue no Brasil e o alerta global da IARC sobre como infecções preveníveis, como HPV e hepatites, continuam associadas a parcela relevante dos cânceres. O episódio recapitula a resolução histórica da OMS sobre hemofilia , o combate do FDA a versões não aprovadas de medicamentos GLP-1 e os novos fluxos de urgência para o manejo do AVC na gestação. Acompanhe a síntese dos fatos que exigem maior preparo técnico e resiliência na prática médica no seu podcast diário de atualização, com curadoria médica e produzido por IA.Afya News. Informação médica confiável e atualizada no seu tempo.Fontes do episódio aqui:⁠https://portal.afya.com.br/podcasts/afya-news/14-02-2026

Esta edição apresenta as lideranças da lista TIME100 Health 2026 e os avanços em inteligência artificial e terapias que estão moldando o futuro da medicina. O boletim detalha o alerta da IARC sobre como a vacinação e o tratamento de infecções preveníveis, como HPV e Hepatite, são estratégicos para a redução global do risco de câncer. Destacamos também o uso de realidade virtual pela OPAS para o treinamento imersivo de profissionais em resposta a vírus respiratórios. Acompanhe as tendências que impactam a sua prática assistencial no seu podcast diário de atualização, com curadoria médica e produzido por IA.Afya News. Informação médica confiável e atualizada no seu tempo.Acesse o link das fontes aqui:https://portal.afya.com.br/podcasts/afya-news/13-02-2026

There has been a shift in cervical cancer screening from primary cytology based to HPV based. Even HPV screening has had its evolution from physician collected samples to patient self-collection, either in a clinical setting or at home with an approved collection system. In May 2025, the FDA cleared the first at-home self-collection kit for HPV screening, specifically the Teal Wand by Teal Health. Now, we are seeing the advent of POSSIBLY another avenue for cervical HPV testing- although it is a bit awkward: the use of menstrual blood as an HPV screening test. In this episode we will review a new cross-sectional, population-based study from China which compared testing menstrual blood for human papillomavirus during cervical cancer screening to clinician-collected cervical samples for human papillomavirus (HPV). This concept, and these results, are not new at all! And there are important limitations to consider at this time. Listen in for details.1. Testing menstrual blood for human papillomavirus during cervical cancer screening in China: cross sectional population based study. BMJ 2026; 392 doi: https://doi.org/10.1136/bmj-2025-084831 (Published 04 February 2026)BMJ 2026;392:e084831https://www.bmj.com/content/392/bmj-2025-0848312. Naseri S, Young S, Cruz G, Blumenthal PD. Screening for High-Risk Human Papillomavirus Using Passive, Self-Collected Menstrual Blood. Obstet Gynecol. 2022 Sep 1;140(3):470-476. doi: 10.1097/AOG.0000000000004904. Epub 2022 Aug 3. PMID: 35926207; PMCID: PMC9377370.3. Fokom Domgue J, Chandra M, Oladoyin O, Desai M, Yu R, Shete S. Women's Preferences for Home-Based Self-Sampling or Clinic-Based Testing for Cervical Cancer Screening. JAMA Netw Open. 2026;9(2):e2558841. doi:10.1001/jamanetworkopen.2025.58841

On the radio show this week we dive into the negative impact of ICE's presence on Minnesota students and their ability to show up to learn. Then we hear about the No Kid Hungry campaign, the importance of SNAP for 14 million food-insecure children, and the need to protect it from funding cuts. We also cover the effectiveness and safety of vaccines, including the HPV vaccine. In closing we discuss the power and importance of storytelling in advocating for health care and disability rights.  SPECIAL GUESTS: Kristen Sinicariello, Columbia Heights, Minnesota School District; Anne Filipic, Share Our Strength, @sharestrength; Dr. Angela Ulrich, Center for Infectious Disease Research and Policy, @cidrap, @cidrap.bsky.social; Elena Hung, Little Lobbyists, @LittleLobbyists, @littlelobbyists.com; 

The p53 protein plays a central role in preventing cancer by responding to cellular stress and DNA damage. When activated, it can repair damaged DNA or trigger cell death, preventing the survival of potentially malignant cells. Loss of p53 function is a hallmark of many cancers. HPV is well known to inactivate p53 through its E6 protein, which promotes p53 degradation. This mechanism contributes to HPV-associated cancers, including cervical, anal, and head and neck cancers. SARS-CoV-2, while not traditionally classified as an oncogenic virus, has been shown to interfere with immune function and, in some cases, with cellular pathways that involve p53. A recent article by Dr. Wafik El-Deiry of The Warren Alpert Medical School of Brown University, published in Oncotarget, proposes a scientific hypothesis suggesting that proteins from HPV and SARS-CoV-2 may both interfere with the body's tumor-suppressing mechanisms, potentially compounding their effects on cancer-related pathways. The Hypothesis: HPV E6 and SARS-CoV-2 Spike Proteins May Cooperatively Suppress p53 In the paper, titled “Hypothesis: HPV E6 and COVID spike proteins cooperate in targeting tumor suppression by p53,” Dr. El-Deiry proposes that the SARS-CoV-2 spike protein, whether introduced via infection or mRNA vaccination, may suppress p53 activity in a manner that complements the effects of HPV E6. In individuals with persistent HPV infection, this combined interference could further reduce p53 function, weakening tumor suppression mechanisms. Full blog - https://www.oncotarget.org/2026/02/09/how-hpv-and-covid-19-spike-proteins-may-interact-to-impact-cancer-suppression/ Paper DOI - https://doi.org/10.18632/oncotarget.28823 Correspondence to - Wafik S. El-Deiry - wafik@brown.edu Abstract video - https://www.youtube.com/watch?v=2GJVmpG4fPk Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28823 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, HPV, COVID, p53, spike To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us on social media: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

After close to a decade of abnormal pap smears, a Cone Biopsy indicated Athena Porter had cervical cancer.  To make sure her diagnosis of endocervical adenocarcinoma didn't spread, she opted for a radical hysterectomy.  With the procedure, her cervix was not the only vital organ removed.  A wife and mother to two daughters, Athena feels blessed that she can return to work on her Iowa farm.    In 2012, she went in for an annual wellness exam.  A pap smear indicated she was HPV+.  Her doctor told Athena a worst-case scenario was cancer, but the virus would likely go away on its own.  She was asked to return in a year.  When she came back, she was still HPV+,  so she underwent a colposcopy, an attempt to get a better look at cells on her cervix.   This led to a LEEP procedure in which cells on her cervix were removed.  The virus was still there, but the procedure showed clean margins.  After more years of being HPV+, in late 2022, Athena underwent a Cone Biopsy, in which a device resembling an ice cream scoop removed cells on her cervix, cells that were sent to the Mayo Clinic.  In early 2023, results came back.  Athena received a phone call at work telling her she had cervical cancer.   Her doctor said by way of treatment, Athena could have only her cervix removed, but she opted for a radical hysterectomy, which would come close to guaranteeing the cancer wouldn't spread.  The hysterectomy removed her cervix, her uterus, the top part of her vagina and her fallopian tubes.  This move came after she and her husband decided their family, including two young daughters, was complete, and that they were okay with having no more children.   Athena was in the hospital for four or five days, then after she was discharged, even with medication, she experienced severe pain when she would stretch or twist.    Athena reached survivorship, and though she would admit her health is not what it was prior to her diagnosis, she feels blessed to be able to return to her office job and work on her Iowa farm.  She also feels blessed that her cancer journey was not as severe as that of others who have also been diagnosed with cervical cancer.   By way of advice, she strongly advises women to get screened for cervical cancer and to get the HPV vaccine.   Additional Resources:   Support Group: Cervivor  https://www.cervivor.org  

Welcome to How Humans Heal. In this episode, I'm going to talk about blood sugar levels and how optimizing them can help you clear high-risk HPV virus to negative and get a normal Pap smear result. As you optimize your blood sugar, you're going to optimize your whole health because when we have optimal blood sugar, we have optimal immune function, optimal hormone levels, lower inflammation, and a healthier microbiome—both gut and vaginal. This means we can prevent cancer, diabetes, heart disease, and dementia while improving energy levels, sleep, focus, memory, and body weight. There are many benefits to optimizing blood sugar, which is why this one of the first things I teach patients. Why Monitor Your Blood Sugar Regularly Even if your blood sugar has been normal for much of your life, a change can happen—whether it's stress or perimenopause or post menopause. Learning what affects your blood sugar may be different for you than for others. Two different people can eat the same thing and have completely different blood sugar responses. This is an opportunity to know your body and track what's going on inside your system. I'm here to help you! LINKS FROM THE EPISODE:   Join Dr. Doni's Kickstart Program: https://hpv.doctordoni.com/hpv/hpv-kickstart-program   Schedule A Chat With Dr. Doni: https://intakeq.com/new/hhsnib/vuaovx    Read the full episode notes and find more information: https://doctordoni.com/blog/podcasts/ MORE RESOURCES FROM DR. DONI:   Quick links to social media, free guides and programs, and more: https://doctordoni.com/links     Disclosure: Some of the links in this post are product links and affiliate links and if you go through them to make a purchase I will earn a commission at no cost to you. Keep in mind that I link these companies and their products because of their quality and not because of the commission I receive from your purchases. The decision is yours, and whether or not you decide to buy something is completely up to you.

(00:00:00) Author Linda Gottfried joins us to share insights from her new book How to Live Your Life Like You’ve Already Won the Lottery, a guide to shifting perspective, embracing abundance, and finding purpose beyond financial luck. She invites readers to rethink what it means to “win” and to cultivate joy in everyday life. (00:16:00) Then, with a grateful heart, Dan Tomaso returns to walk us through last week’s powerful winter storm — what drove its intensity, how it compares to past systems, and what Pennsylvanians can expect for the rest of the season. (00:27:29) Finally, Dr. Josh Kesterson helps us mark Cervical Cancer Awareness Month with essential, empowering information. We discuss what cervical cancer is, the symptoms women should watch for, why HPV vaccination and regular screening remain the strongest tools for prevention, and how advances in imaging, treatment, and mobile health services are expanding access. Dr. Kesterson also outlines the resources available through UPMC Hillman Cancer Center and UPMC Magee‑Women for women who may face barriers to care. Support WITF: https://www.witf.org/support/give-now/See omnystudio.com/listener for privacy information.

Join primary care physicians Kate Rowland, Gary Ferenchick, Henry Barry and Mark Ebell as they discuss 4 new POEMs (Patient Oriented Evidence that Matters): cardiovascular outcomes of GIPs (vs GLP), risk-based breast cancer screening (WISDOM Trial), whether a single dose of HPV vaccine is as good as two, and surgery (or not) for shoulder impingement syndrome. Plus Kate has a great Groundhog Day quiz!

El virus del papiloma humano (VPH o HPV del ingles human papillomavirus) son grupos diversos de virus AND pertenecientes a la familia de los Papillomaviridae y representa una de las enfermedades de transmisión sexual mas comunes, y se conocen mas de 100 tipos virales. Entre 30 y 40 tipos de VPH se transmiten normalmente por contacto sexual. El herpes genital es una infección de transmisión sexual (ITS), causada por el virus del herpes simple (VHS). Hay dos tipos de VHS. El VHS-1 generalmente afecta la boca y los labios y causa herpes labial (aftas) o herpes febril. Sin embargo, se puede transmitir de la boca a los genitales durante el sexo oral. El VHS-2 casi siempre causa el herpes genital y se puede transmitir a través de secreciones (líquidos) orales o genitales. Puede obtener este Programa en LA Farmacia Natural en Los Angeles, Van Nuys, Huntington Park, El Monte, Arleta, Pico Rivera, Long Beach y en Burbank o llamando a la Línea de la Salud, al 1-800-227-8428 si desean que se lo enviemos a su casa.

V audioknihe Urostorky vás urológ Ján Švihra ml. prevedie svetom bizarných, vtipných a šokujúcich príbehov a historiek z nemocnice, pričom sa nevyhne ani dôležitej osvete v oblasti urológie, ktorá je žiaľ stále vnímaná ako tabu. Časopis Forbes ho zaradil medzi najvplyvnejších lekárov na sociálnych sieťach na Slovensku. Dozviete sa tiež odpovede na otázky, ktoré ste sa možno báli opýtať: Kedy sa môže penis zlomiť a kedy bude pripomínať papriku? Záleží na veľkosti? Ako sa ženy vedia vyhnúť zápalom močového mechúra a úniku moču? Aký je správny pitný režim, aby nerástli močové kamene – a dajú sa rozpustiť pivom? Má obriezka v dnešnej dobe ešte zmysel? Ako na naše pohlavné zdravie a riziko rakoviny vplýva vírus HPV? Bonusom tejto audioknihy sú názory a rady od odborníkov a známych influencerov. Po jej vypočutí sa už nebudete báť urológie a pri niektorých príbehoch sa určite poriadne zasmejete. Audiokniha: Urostorky Autor: Ján Švihra Interpret: Mário Zeumer Dĺžka: 5:17 h Vydavateľstvo: Publixing a INTEREZ MEDIA Audiokniha Urostorky na webe Publixing (MP3 na stiahnutie) Audiokniha Urostorsky na webe Audiolibrix (MP3 na stiahnutie)

In this episode of ECDC On Air, we speak with ECDC's Helena de Carvalho Gomes - Deputy Head of Unit for Scientific Evidence and Communication, and former clinician in obstetrics and gynaecology, about the role of human papillomavirus (HPV) in cervical cancer and how vaccination and screening can prevent the disease.Drawing on her clinical experience, she reflects on changes in cervical cancer prevention over the past 25 years and on the impact of HPV vaccination and screening in reducing pre-cancerous lesions and cancer risk among women.We also discuss why sustained vaccination programmes and regular cervical screening (Pap smear or Papanicolaou test) remain essential for reducing cervical cancer across Europe and moving towards its elimination.Want to know more about HPV and its connection to cervical cancer?Read more on the European Vaccination Information Portal in YOUR language here.Find out more about HPV on the disease page on ECDC Portal.More information on epidemiology in Europe in general can be found on our portal: https://⁠ecdc.europa.eu⁠ and ⁠social media channels⁠.Enjoy the episode!

Kenya's national action plan to eliminate cervical cancer by 2030 offers renewed hope for girls and women in rural communities, where access to prevention and care has often been limited. Aligned with World Health Organization (WHO)'s targets, the plan focuses on free vaccines to prevent human papillomavirus (HPV) infection – which can lead to various cancers including cervical cancer – providing early screening and timely treatment.Joseph Mogga with WHO's office in Nairobi, spoke to UN News's Assumpta Massoi and explained how by bringing services closer to where women live, Kenya is signalling a strong, positive commitment to ensure that no girl or woman is left behind – especially when it comes to cervical cancer prevention.

TWiV reviews the finding in Sweden that immunization against cervical cancer with human papillomavirus vaccine also protects the non-immunized, and methyl salicylic acid as a key volatile molecule that attracts parasitoid wasps to rice and other crops to destroy destructive leafhoppers, and is down-regulated by virus infection to enable virus spread. Hosts: Vincent Racaniello, Rich Condit, and Kathy Spindler Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Support science education at MicrobeTV ASV 2026 Positions in Rosenfeld Lab (email) "Host adaptations to viral infections" International Meeting William Foege dies (NY Times) Peter Duesberg dies (NY Times) US gov't lost over 10,000 PhDs under DJT (Science) Herd effect of HPV vaccination (Lancet Pub Health) Arboviruses manipulate rice's volatile emissions (Sci Adv) Letters read on TWiV 1293 Timestamps by Jolene Ramsey. Thanks! Weekly Picks Kathy - The Beak of the Finch, by Jonathan Weiner Rich - Washington: A Life by Ron Chernow Vincent - The Man from Beijing by Henning Mankell Intro music is by Ronald Jenkees Send your virology questions and comments to twiv@microbe.tv Content in this podcast should not be construed as medical advice.

January is Cervical Cancer Awareness Month, and while many people know HPV causes cervical cancer, far fewer realize HPV can also lead to vulvar, vaginal, anal, oral, and penile cancers.In this episode of the Sky Women's Health Podcast, Dr. Carolyn Moyers is joined by Dr. Nisha Patel (@drplantel), who shares her personal experience navigating an unexpected HPV-related precancer diagnosis. This is an honest, patient-centered conversation about what happens when HPV shows up outside the cervix — and why symptoms are often overlooked.We discuss abnormal Pap smears, persistent vulvar symptoms, delayed diagnosis, and why biopsy matters when something doesn't feel right. If you've ever been told “everything looks normal” but still had concerns, this episode will resonate.In This Episode, We Discuss:HPV and its link to cervical cancerHPV-related vulvar, vaginal, anal, oral, and penile cancersWhy HPV is extremely common — and why stigma is harmfulWhy Pap smears don't detect all HPV-related diseaseHow vulvar symptoms can be missed or minimizedWhat it feels like to receive a precancer diagnosisWhen biopsy is necessaryHow patients can advocate for themselvesWhy This Conversation MattersHPV is one of the most common sexually transmitted infections worldwide. Early detection and awareness — beyond Pap smears alone — are critical to preventing HPV-related cancers. This episode expands the cervical cancer conversation to include whole-body HPV awareness.About Our GuestDr. Nisha Patel is a physician and health educator who uses her platform @drplantel to share honest conversations about healthcare, advocacy, and lived experience. In this episode, she speaks openly as a patient to help others feel informed and empowered.

In this episode, Dr. Beverly London, a gynecologist at Carle Foundation Hospital, shares groundbreaking updates on cervical health awareness, including the innovative self-collection method for Pap screening. Discover how this new approach is making cervical cancer screening more accessible and comfortable for women. Tune in to learn about the importance of regular screening, new HPV testing guidelines, and how this can save lives. Don't miss out on this vital information—visit Carle.org for more insights!  Learn more about Beverly London, MD 

Podcast analisa as primeiras evidências de que a vacinação contra o HPV está reduzindo a incidência de tumores de colo do útero no Brasil. E mais: apito; jumentos; astrobiologia

Episode Summary In this episode of Please Me Podcast, Eve Hall delivers an in-depth, sex-positive, medically informed conversation on sexual health, pleasure, and prevention for all genders. This episode covers how blood flow, hormones, nutrition, and self-knowledge directly impact arousal, erections, lubrication, orgasm, and long-term sexual wellness. Eve breaks down why erectile dysfunction and vaginal dryness are often early warning signs of vascular health issues, why masturbation is an essential solo practice, and how understanding your own body is key to closing the orgasm gap. She also emphasizes the importance of STI testing, informed consent, and being prepared for safer sex — especially during the holidays and periods of increased sexual activity. Listeners will gain practical tools, education, and prevention strategies to support confident, pleasurable, and safer sex at every stage of life. Sexual health as a reflection of overall cardiovascular and vascular health Erectile dysfunction, endothelial dysfunction, and blood flow Acoustic wave therapy for erectile and vaginal health Penis pumps, traction devices, and penile tissue health Masturbation, ejaculation frequency, and prostate health Female arousal anatomy, clitoral blood flow, and vaginal lubrication The importance of foreplay and arousal time Hormones and sexual function (testosterone, estrogen, progesterone, DHEA) Vaginal dryness, tissue thinning, and pain with sex Nutrition, micronutrients, hydration, sleep, and movement for sexual wellness Masturbation as self-care and pleasure literacy The orgasm gap in heterosexual relationships Communicating sexual needs with partners STI prevention, testing, and informed consent Oral and anal STI testing and why it matters Doxy-PEP and post-exposure STI prevention Sexual health “bug-out bags” and safer sex preparedness Yeast infections and UTIs related to sexual activity Herpes education and antiviral treatment HPV education, transmission, cancer risk, and vaccination Prevention-focused sexual healthcare and long-term intimacy Website: https://pleaseme.onlineSocial Media & Contact: https://pleaseme.online/contactsSubstack Newsletter: https://pleaseme.substack.comPatreon: https://patreon.com/PleaseMePodcastBe a Guest on Please Me (PodMatch):https://www.podmatch.com/hostdetailpreview/beaguestonpleasemepodcast Topics Discussed in This EpisodeConnect with Eve & Please Me Learn more about your ad choices. Visit megaphone.fm/adchoices

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-469 Overview: Tune in to hear how self-collected vaginal human papillomavirus (HPV) testing has potential to expand access to cervical cancer screening and reduce barriers for your patients. This episode reviews cervical cancer screening guidelines, follow-up recommendations, and how to consider offering self-collection as an option to increase screening rates and improve preventive care in your practice. Episode resource links: CA CancerJClin.2026;e70041. DOI:10.3322/caac.70041 US Food and Drug Administration (FDA). Device Classification Under Section 513(f)(2)(De Novo). Device for home collection and transport of vaginal specimens by lay users for use in an approved HPV molecular assay. FDA; 2025. FranklySpeaking@pri-med.com  The views expressed in this podcast are those of Dr. Domino and his guests and do not necessarily reflect the views of Pri-Med.

In this episode of the Oncology Brothers podcast, we dived into the current treatment landscape for head and neck cancer. We welcomed Dr. Fangdi Sun, a head and neck medical oncologist from Stanford University, to discuss key topics including: • The importance of initial workup and the role of biomarkers, including HPV and EBV testing. • Treatment paradigm for early-stage and locally advanced head and neck cancers, focusing on the differences between HPV-positive and HPV-negative disease. • The evolving role of immunotherapy and the new perioperative approaches in treatment. • Insights into managing metastatic disease, including the use of PD-L1 scores and systemic therapy options. • The significance of multidisciplinary collaboration in optimizing patient care. Whether you're a healthcare professional or simply interested in oncology, this episode provides valuable insights into the complexities of head and neck cancer treatment. Don't miss out on this informative discussion! Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Subscribe to our channel for more episodes as we continue to bridge the gap in oncology! #HeadAndNeckCancer, #HPV, #Immunotherapy, #MultidisciplinaryCare, #OncologyBrothers

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-469 Overview: Tune in to hear how self-collected vaginal human papillomavirus (HPV) testing has potential to expand access to cervical cancer screening and reduce barriers for your patients. This episode reviews cervical cancer screening guidelines, follow-up recommendations, and how to consider offering self-collection as an option to increase screening rates and improve preventive care in your practice. Episode resource links: CA CancerJClin.2026;e70041. DOI:10.3322/caac.70041 US Food and Drug Administration (FDA). Device Classification Under Section 513(f)(2)(De Novo). Device for home collection and transport of vaginal specimens by lay users for use in an approved HPV molecular assay. FDA; 2025. FranklySpeaking@pri-med.com  The views expressed in this podcast are those of Dr. Domino and his guests and do not necessarily reflect the views of Pri-Med.

In his weekly clinical update, Dr. Griffin and Vincent Racaniello discuss screwworm, how the shingles vaccination slows biological aging (for all of you who want to reset 'the clock' and live forever…..you know who you are Musk, Bezos) and getting one dose of the HPV vaccine, then Dr. Griffin then deep dives into recent statistics on RSV, influenza and SARS-CoV-2 infections, the Wasterwater Scan dashboard, Johns Hopkins measles tracker, how losing our elimination status is the cost of doing business (going for broke is never a good business model !) where to find PEMGARDA, how to access and pay for Paxlovid, long COVID treatment center, the effectiveness of this season's influenza vaccine, where to go for answers to your long COVID questions and contacting your federal government representative to stop the assault on science and biomedical research. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode New World Screwworm: Outbreak Moves into Northern Mexico……with an official tag "This is an official CDC Health Advisory" (CDC: Health Alert Network) Association between shingles vaccination andslower biological aging: Evidence from a U.S. population-based cohort study (The Journals of Gerontology series A) Noninferiority of One HPV Vaccine Dose to Two Doses (NEJM) Herd effect of human papillomavirus vaccination on incidence of high-grade cervical lesions: (LANCET: Public Health) Confirmations of Highly Pathogenic Avian Influenza in Commercial and Backyard Flocks (USDA: Animal and Plant Health Inspection Service) Detections of Highly Pathogenic Avian Influenza in Wild Birds (USDA: Animal and Plant Health Inspection Service) Delaware, Georgia see major commercial avian flu outbreaks (CIDRAP) Wastewater for measles (WasterWater Scan) Notes from the Field: Wastewater Surveillance for Measles Virus During a Measles Outbreak — Colorado, August 2025 (CDC: MMWR) Notes from the Field: Retrospective Analysis of Wild-Type Measles Virus in Wastewater During a Measles Outbreak — Oregon, March 24–September 22, 2024 (CDC: MMWR) Measles cases and outbreaks (CDC Rubeola) Measles vaccine recommendations from NYP (jpg) Tracking Measles Cases in the U.S. (Johns Hopkins) Utah measles total rises to 216; CDC deputy director says losing elimination status'cost of doing business' (CIDRAP) Weekly measles and rubella monitoring (Government of Canada) Measles (WHO) Get the FACTS about measles (NY State Department of Health) Measles (CDC Measles (Rubeola)) Measles vaccine (CDC Measles (Rubeola)) Presumptive evidence of measles immunity (CDC) Contraindications and precautions to measles vaccination (CDC) Adverse events associated with childhood vaccines: evidence bearing on causality (NLM) Measles Vaccination: Know the Facts (ISDA: Infectious Diseases Society of America) Deaths following vaccination: what does the evidence show (Vaccine) Assessing MMR vaccination coverage gaps in US children with digital participatory surveillance (Nature Health) Influenza: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) Respiratory virus activity levels (CDC Respiratory Illnesses) Weekly surveillance report: clift notes (CDC FluView) Effectiveness of influenza vaccination to prevent severe disease: a systematic review and meta-analysis of test-negative design studies (CMI: Clinical Microbiology and Infection) Interim vaccine effectiveness against influenza virus among outpatients, France, October 2025 to January 2026 (Eurosurveillance) Moderate protection from vaccination against influenza A(H3N2) subclade K in Beijing, China, September to December 2025 (Eurosurviellance) Current flu vaccine provides moderate protection against severe disease, interim analyses suggest (CIDRAP) OPTION 2: XOFLUZA $50 Cash Pay Option (xofluza) RSV: Waste water scan for 11 pathogens (WastewaterSCan) Respiratory Diseases (Yale School of Public Health) USrespiratory virus activity (CDC Respiratory Illnesses) RSV-Network (CDC Respiratory Syncytial virus Infection) Vaccines for Adults (CDC: Respiratory Syncytial Virusnfection (RSV)) Economic Analysis of Protein Subunit and mRNA RSV Vaccination in Adults aged 50-59 Years (CDC: ACIP) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 deaths (CDC) Respiratory Illnesses Data Channel (CDC: Respiratory Illnesses) COVID-19 national and regional trends (CDC) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Where to get pemgarda (Pemgarda) EUAfor the pre-exposure prophylaxis of COVID-19 (INVIYD) Infusion center (Prime Fusions) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Drug interaction checker (University of Liverpool) Help your eligible patients access PAXLOVID with the PAXCESS Patient Support Program (Pfizer Pro) UnderstandingCoverageOptions (PAXCESS) Infectious Disease Society guidelines for treatment and management (ID Society) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) Managing healthcare staffing shortages (CDC) Anticoagulationguidelines (hematology.org) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia : Columbia University Irving Medical Center) The answers: Long COVID Reaching out to US house representative Letters read on TWiV 1290 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv Content in this podcast should not be construed as medical advice.

Have you gotten an abnormal Pap smear result and tested positive for high-risk HPV virus? Are you searching online and getting confused because there's so much conflicting information that it ends up spiraling into paralysis of not knowing what to do? You're in the right place because I'm going to be breaking down six of the most common myths and misconceptions about high-risk HPV and abnormal pap smear results so that we can set the record straight and you can get to helping your body heal. I'm Dr. Doni Wilson. I'm a women's health expert, a naturopathic doctor and midwife, and I've been helping women with abnormal pap smears for over 25 years. That means I've helped thousands of women in this situation. When you're looking for information online, you may or may not be getting information from someone who has this much experience helping women reverse an abnormal pap smear and get rid of HPV once and for all. I'm here to help you! LINKS FROM THE EPISODE:   Join Dr. Doni's "Say Goodbye To HPV" Program: https://hpv.doctordoni.com/hpv/checkout-12week-program   Schedule A Chat With Dr. Doni: https://intakeq.com/new/hhsnib/vuaovx    Read the full episode notes and find more information: https://doctordoni.com/blog/podcasts/ MORE RESOURCES FROM DR. DONI:   Quick links to social media, free guides and programs, and more: https://doctordoni.com/links     Disclosure: Some of the links in this post are product links and affiliate links and if you go through them to make a purchase I will earn a commission at no cost to you. Keep in mind that I link these companies and their products because of their quality and not because of the commission I receive from your purchases. The decision is yours, and whether or not you decide to buy something is completely up to you.

We unpack new studies that reshape how we counsel on VBAC after short intervals, update what we tell BRCA carriers about estrogen therapy, and explore how self-collected HPV tests can reduce screening gaps. We also question surgical marketing, workforce trends, and the shaky evidence behind aspirin dosing for preeclampsia.• Short interpregnancy interval as a VBAC risk factor, not a contraindication• Absolute uterine rupture rates in spontaneous vs induced labor• Estrogen therapy in BRCA carriers and treated gyn cancers• Cervical screening overuse and underscreening in insured populations• Self-collected HPV testing intervals and access benefits• OB-GYN workforce shortages and rural distribution gaps• Endometriosis surgery indications versus fertility claims• Robotics versus laparoscopy outcomes and training priorities• Aspirin dose trials, lack of placebo arms, and abruption signals• Reading statistics correctly and demanding better editorial standards0:00 Setting The Agenda: New Studies0:40 Short Interval Pregnancy And VBAC Risk3:10 Quantifying Uterine Rupture By Spacing8:10 Induction, Augmentation, And Rupture Math9:40 HRT In BRCA Carriers: New Evidence13:05 Estrogen After Gyn Cancers: Practice Gaps17:40 Cervical Screening: Overuse And Underscreening22:30 Self-Collected HPV Testing Guidance27:00 OB-GYN Shortages And Distribution33:20 Endometriosis Surgery And Fertility Claims41:20 Robotics Vs Laparoscopy: Outcomes And Training47:20 Aspirin Dosing For Preeclampsia: No Signal55:30 Interpreting Stats And Editorial Standards59:20 Closing Notes And Next StepsBe sure to check out thinking about obgyn.com for more information, and be sure to follow us on InstagramFollow us on Instagram @thinkingaboutobgyn.

前一陣子看到了李函拍攝的HPV人類乳突病毒衛教宣導影片，很驚訝竟然有宣導影片可以拍得那麼有質感。 自己認真查了一下才發現原來對於HPV有那麼多的迷思！ 所以今天我們再次邀請到Kiwi李函來和我們聊聊上一次我們沒有聊完的話題～ 一起來聽聽李函在時裝周和時尚圈遇到的不同狀況，還有出國遇到豔遇後發生的意外驚喜吧

Turn online alignment into an offline community — join us at TheWayFwrd.com to connect with like-minded people near you.When did we decide women's bodies couldn't be trusted to give birth?Childbirth is often the first place we're taught to override intuition in favor of authority. In this episode, I speak with Dr. Nathan Riley about how modern systems shape pregnancy and birth — not just medically, but psychologically and culturally.This conversation isn't about rebellion or nostalgia. It's about responsibility, trust, and what happens when we're trained to hand those over.We talk about natural birth, home birth, and the power of doing less instead of more. C-section rates keep climbing and fear is introduced early through institutional rituals. Education, compliance, and credentialed authority train us to outsource knowing, especially during pregnancy and birth. From midwifery to birth trauma, from holistic health to reclaiming responsibility, this conversation connects dots most people never think to question.If you're interested in birth sovereignty, health sovereignty, and the deeper implications of how humans enter the world, this episode will challenge you. Not with ideology, but with lived experience and uncomfortable clarity.You'll Learn:[00:00] Introduction[04:07] Meeting Dr. Stu Fishbein at a breech delivery talk and the home birth that changed everything[13:53] Why compulsory education conditions us to trust credentials over critical thinking and clinical experience[27:53] The alternative health movement is still rooted in materialism [39:01] The overuse of the word physiology when being directed towards childbirth[52:35] Where the alternative health space is getting it wrong[01:06:53] How asking about your own birth transforms your ability to hold space and trust intuition during labor[01:16:40] Induction risks depend on your provider and why most inductions aren't medically necessary[01:29:14] The HPV and cervical cancer story[02:02:03] The graphic reality of circumcision[02:22:10] Why midwives should be the default for prenatal care[02:50:55] The nuanced case for free birth, the problems with rebirth certifications, and why "birth educator" replaced "midwife"Related The Way Forward Episodes:Rethinking DNA: Examining the Evidence with Dr. Tom Cowan | YouTubeThe Heart is Not a Pump: Vortexes, Blood Flow & The Seat of the Soul with Dr. Stephen Hussey | YouTubeThe Great Birth Revival: Birth Certificates, Circumcision, Postpartum & More with Veda Ray | YouTubeFlipping Birth Upside Down with Eyla Cuenca | YouTubeResources Mentioned:The Secret Life of the Unborn Child: Dr. Thomas Verny on the Embodied Mind, Epigenetics, and Transgenerational Healing | Podcast50 Human Studies, in Utero, Conducted in Modern China, Indicate Extreme Risk for Prenatal Ultrasound by Jim West | Book or AudiobookLearn more from Dr. Nathan Riley:Born Free Method | WebsiteBeloved Holistics | Website2026 Born Free Twins-Breech Gathering | WebsiteFind more from Alec:Alec Zeck | InstagramAlec Zeck | XThe Way Forward | InstagramThe Way Forward is Sponsored By:Designed for deep focus and well-being. 100% blue light and flicker free. For $50 off your Daylight Computer, use discount code: TWF50New Biology Clinic: Redefine Health from the Ground UpExperience tailored terrain-based health services with consults, livestreams, movement classes, and more. Visit www.NewBiologyClinic.com and use code THEWAYFORWARD (case sensitive) for $50 off activation. Members get the $150 fee waivedRMDY Academy & Collective: Homeopathy Made AccessibleHigh-quality remedies and training to support natural healing.Enroll hereExplore here

The American Cancer Society has updated guidelines for cervical cancer screening to include self-collected specimens to assess for human papilloma virus, or HPV. William Nelson, director of the Kimmel Cancer Center at Johns Hopkins, explains why. Nelson: There's 200,000 women … Will women soon be testing themselves for human papilloma virus, or HPV ? Elizabeth Tracey reports Read More »

Women may now choose to collect their own samples to test for human papilloma virus, or HPV as part of their screening regimen for cervical cancer, the American Cancer Society now says. Kimmel Cancer Center director William Nelson at Johns … Since most cervical cancer is caused by infection with a virus, when should screening start? Elizabeth Tracey reports Read More »

Doctors have long recommended regular cervical cancer screenings. Traditionally doctors perform these exams using a speculum, which often say is uncomfortable and, for many, quite painful. Some recent developments could make a large number of these screenings easier. In early January, the Health Resources and Services Administration, which is part of the Department of Health and Human Services, updated its guidelines to say that self-administered tests are an acceptable way to screen for human papillomavirus. HPV is a sexually-transmitted disease that causes the majority of cervical cancer cases. OB-GYNs are hopeful that at-home testing will make cervical cancer screenings easier to access…. and significantly more comfortable. Guests: Dr. Linda Eckert, professor of Obstetrics and Gynecology at the University of Washington School of Medicine Related links: New Guidelines Endorse Self-Swab Alternative to Pap Smear for Cervical Cancer Testing - The New York Times Cervical Cancer Risk Factors | Cervical Cancer | CDC The FDA has approved an at-home HPV test. What you need to know : NPR Thank you to the supporters of KUOW, you help make this show possible! If you want to help out, go to kuow.org/donate/soundsidenotes Soundside is a production of KUOW in Seattle, a proud member of the NPR Network.See omnystudio.com/listener for privacy information.

Last week the federal government reduced the number of vaccines it recommends for children in the US from 17 to 11. The CDC made these changes without the approval from a federal panel. On today's show, host Douglas Haynes takes a look at these changes and their implications for public health with two experts, Mary Hayney of the UW School of Pharmacy and Kia Kjensrud of Immunize Wisconsin.  They break down the latest 6 changes to recommendations for the HPV, Hepatitis A, Rotavirus, RSV, flu and covid, and Meningococcal vaccines. The difference is that now the CDC doesn't recommend these vaccines, they say “talk to your doctor about them” through a process known as “shared clinical decision-making.” From the point of a published vaccine schedule, the CDC's new recommendations make it appear as if these vaccines are optional, says Hayney. And the changes imply that there hasn't been shared clinical decision-making, though it is common practice already, says Kjenstrud. At the end of the day, there is no scientific basis for these changes and the majority of parents still want their children to be vaccinated, says Hayney. For those who are skeptical about vaccines, Kjensrud says that vaccines are under strict scrutiny. More than 200 groups have joined the American Association of Pediatrics in calling for oversight for these changes. The rationale from the Trump administration is that these changes are in line with other countries like Denmark that recommend fewer childhood vaccines. Hayney says that there are significant demographic differences–in terms of size and diversity– between these countries to make it hard to compare. In addition, universal healthcare covers all citizens in Denmark. They also discuss the trust that pediatricians build with the families they care for, how measles and the flu are deadly and preventable diseases, school attendance policies, the misconception that physicians are making money from these childhood vaccines, and how insurance policies will be affected by these new guidelines.  Mary S. Hayney is a Distinguished Professor of Pharmacy at the University of Wisconsin School of Pharmacy and a Master of Public Health Program Faculty Member at the University of Wisconsin School of Medicine and Public Health/ Her research lab studies vaccine responses in immunocompromised individuals. She teaches immunology topics at the School of Pharmacy, including the immunization course for pharmacy students. Kia Kjensrud has served as the executive director of the Wisconsin Chapter of the American Academy of Pediatrics since 2007. She is the interim director of Immunize Wisconsin, a statewide coalition supporting efforts around strengthening vaccination ecosystems at the local, regional, and statewide level. Featured image of a child receiving a vaccine. Did you enjoy this story? Your funding makes great, local journalism like this possible. Donate hereThe post The CDC Endangers Public Health and Abandons Science appeared first on WORT-FM 89.9.

The CDC announced Monday a major overhaul of the U.S. childhood vaccine schedule, reducing the number of routine immunizations recommended for children. In December, President Trump directed Health and Human Services officials to examine how other developed nations schedule vaccines and to reconsider the U.S. approach. FDA Commissioner Dr. Marty Makary said the changes are intended to restore public trust in health institutions that was lost during the pandemic. However, criticism has been fierce. Lawmakers on both sides of the aisle have pushed back, and the American Academy of Pediatrics has called the move dangerous and unnecessary. Vaccine schedules are handled by the states, meaning states may continue to mandate certain vaccines for school attendance. The updated recommendations also do not eliminate insurance coverage for any vaccines. The CDC changes create three categories. The eleven vaccines that remain in the recommended category include measles, mumps, rubella, polio, pertussis, HPV, and chickenpox. A second category recommends vaccines for individuals considered high-risk, including hepatitis A and B and RSV. The third category includes vaccines available by personal choice after consultation with a doctor, including COVID-19, flu, rotavirus, and others. Earlier this week, former CDC Director Dr. Robert Redfield joined FOX News Rundown host Jessica Rosenthal to discuss the new and reduced childhood vaccine schedule recommendations. Dr. Redfield, author of the new book Redfield's Warning: What I Learned (But Couldn't Tell You) Might Save Your Life, explained why he supports the changes, while also emphasizing the importance of doctors clearly explaining the benefits of vaccines. He also discussed why public trust has eroded and why encouraging vaccine choice and transparency could ultimately lead more Americans to get the shots needed to protect themselves from disease. We often have to cut interviews short during the week, but we thought you might like to hear the full conversation. Today on Fox News Rundown Extra, we share our entire interview with former CDC Director Dr. Robert Redfield—and more of his perspective on vaccines. Learn more about your ad choices. Visit podcastchoices.com/adchoices

In this episode I'm going to help you understand your Pap smear and colposcopy results, particularly if you have an abnormality. Abnormal cells on the cervix are referred to as "dysplasia," and that means high-risk HPV (human papilloma) virus is active and now is the time to prevent it from getting worse. I want to help you understand what your results mean and what your options are. I've seen so many different scenarios involving women of all ages and backgrounds from around the world. I've put my attention into helping women prevent cervical cancer, vaginal cancer, and other forms of HPV-related cancer. I've developed a protocol that has successfully helped women clear high-risk HPV all the way to negative and maintain that status, preventing the virus from causing cancer. I'm here to help you! LINKS FROM THE EPISODE:   Sign up for Dr. Doni's 5-Day HPV Workshop: https://doctordoni.com/HPV-workshop/   Schedule A Chat With Dr. Doni: https://intakeq.com/new/hhsnib/vuaovx    Read the full episode notes and find more information: https://doctordoni.com/blog/podcasts/ MORE RESOURCES FROM DR. DONI:   Quick links to social media, free guides and programs, and more: https://doctordoni.com/links     Disclosure: Some of the links in this post are product links and affiliate links and if you go through them to make a purchase I will earn a commission at no cost to you. Keep in mind that I link these companies and their products because of their quality and not because of the commission I receive from your purchases. The decision is yours, and whether or not you decide to buy something is completely up to you.  

Cervical cancer is one of the most preventable cancers, and when caught early, it's often highly curable. In fact, reports say Australia is on track to eliminate cervical cancer by 2035. However, many women still have unanswered questions about symptoms, screening and what a diagnosis really means. In this Baptist HealthTalk episode, host Johanna Gomez sits down with Dr. Ryan Kahn, a gynecologic oncologist with Baptist Health Cancer Care, to answer the most searched questions women have about cervical cancer. They cover why early stages are often symptom-free, the warning signs to watch for, how survival rates change by stage and what treatment can look like (surgery, chemo, radiation and newer targeted therapies). Dr. Kahn also clears up common misconceptions about HPV, the HPV vaccine and how often you actually need a Pap/HPV test. Listen now for clear, practical guidance to help you protect your health.If you're due for screening, or noticing changes, this episode helps you know what to do next.Host:Johanna GomezAward-Winning Host & JournalistGuest:Ryan Kahn, M.D. Gynecologic OncologistBaptist Health Cancer Care

Starting 2026 off with a bang! This week the honks read listener submitted stories about STDs. Harper's latex “allergy”, gabby has HPV, Lee doesn't think he does, a guy with long blonde hair and a bottle of whiskey in a dark place, lots of herpes, lots of cheating, gonorrhea, chlamydia, a brothers lie, hippies, more herpes, and the importance of breaking the stigma. Enjoy! Find & instantly book doctors appointments with ZocDoc @ http://zocdoc.com/HONK If you love the show and want to support us, join our growing community on Patreon to see what we're giving for $5 a month! JOIN OUR PATREON https://www.patreon.com/teatime42069 Send your stories to TeaTimeStories42069@gmail.com Watch Harper-Rose's set here: https://www.youtube.com/watch?v=4eNpjjGZHLY&t=110s Watch Gabby Lamb's set here: https://www.youtube.com/watch?v=J7oOYWgK598